Filing Flows › Abbott Laboratories (ABT) › R&D spending
Abbott Laboratories (ABT) R&D spending by quarter
Abbott Laboratories' R&D spending was $920M in Q3 2026 (third quarter 2026), +3% from Q2 2026. Over the last 7 quarters it ranged from $716M (Q1 2025) to $920M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $920M | +3% | +20% |
| Q2 2026 | $892M | +16% | +23% |
| Q1 2026 | $767M | +4% | +7% |
| Q4 2025 | $735M | -4% | — |
| Q3 2025 | $766M | +6% | — |
| Q2 2025 | $725M | +1% | — |
| Q1 2025 | $716M | — | — |
Q3 2026 at a glance
Abbott Laboratories, Q3 2026: revenue $13.0B (+14% year over year), operating margin 10.4%, net earnings $920M, operating cash flow $1.7B. The chart follows the revenue to costs, profit and cash.
Questions
What is Abbott Laboratories' R&D spending?
Abbott Laboratories' R&D spending was $920M in Q3 2026 (third quarter 2026), +3% from Q2 2026.
How has Abbott Laboratories' R&D spending changed?
Over the last 7 quarters it ranged from $716M (Q1 2025) to $920M (Q3 2026).